Gretchen M Schroeder

This inventor holds 15 USPTO granted patents, plus 2 CIPO patents and 6 EPO patents, primarily in Kinase Inhibitors. Top assignees: Bristol-Myers Squibb Compnay, Bristol Meyers Squibb Company. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gretchen M Schroeder. Retrieved from https://idiyas.com/inventor/gretchen-m-schroeder

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 6)

Average Co-Inventor Count = 5.0

ph-index = 5

Forward Citations = 105(Granted Patents)

Company Filing History:

14 out of 3,746

Bristol-Myers Squibb Compnay

patents

1 out of 41

Bristol Meyers Squibb Company

patents

Years Active: 2007-2026

Loading Chart...

Areas of Expertise:

Benzofuran Compounds

CXCR4 Antagonists

Tubulysin Analogs

Macrocyclic Benzodiazepines

Sulfonamides

JAK2 Inhibitors

Pyridinone Compounds

Monocyclic Heterocycles

Oxalamide Derivatives

Pyrrolotriazine

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12673954 - Benzofuran compounds as sting agonists (2026-07-07),

2. 10450318 - CXCR4 receptor antagonists (2019-10-22),

3. 10077287 - Tubulysin analogs and methods of making and use (2018-09-18),

4. 9902740 - Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses (2018-02-27),

5. 9688694 - Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses (2017-06-27),

6. 9346795 - Substituted sulfonamides useful as antiapoptotic Bcl inhibitors (2016-05-24),

7. 8673933 - JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer (2014-03-18),

8. 8536200 - Pyridinone compounds (2013-09-17),

9. 8202881 - JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer (2012-06-19),

10. 7989477 - Monocyclic heterocycles as kinase inhibitors (2011-08-02),

11. 7851489 - Pyridinone compounds (2010-12-14),

12. 7714138 - Monocyclic heterocycles as kinase inhibitors (2010-05-11),

13. 7470693 - Oxalamide derivatives as kinase inhibitors (2008-12-30),

14. 7459562 - Monocyclic heterocycles as kinase inhibitors (2008-12-02),

15. 7173031 - Pyrrolotriazine kinase inhibitors (2007-02-06),

Title: The Innovative Contributions of Gretchen M. Schroeder

Introduction: Gretchen M. Schroeder is an accomplished inventor based in Ewing, NJ, known for her significant contributions to the field of pharmaceutical sciences. With a total of 14 patents to her name, she has made a notable impact through her innovative research and inventions aimed at treating various medical conditions.

Latest Patents: Among her latest patents, two noteworthy inventions stand out. The first is related to CXCR4 receptor antagonists. This invention encompasses compounds of formula I, which are identified as antagonists of the CXCR4 receptor. The patent includes pharmaceutically acceptable salts, compositions, methods of producing these compounds, and their therapeutic applications. The second patent focuses on tubulysin analogs and their methodologies. These analogs possess anti-mitotic properties, making them effective in cancer treatment, especially when attached to a targeting moiety.

Career Highlights: Throughout her career, Gretchen has worked with prestigious organizations, including Bristol-Myers Squibb Company. Her expertise and innovative thinking have propelled her to be recognized in the pharmaceutical industry for her significant developments in drug efficacy.

Collaborations: Gretchen M. Schroeder has collaborated with esteemed colleagues such as Robert Michael Borzilleri and Heidi L. Perez. These collaborations have fostered an environment for innovative ideas and advancements in her research endeavors, enhancing the potential of her inventions.

Conclusion: Gretchen M. Schroeder is a remarkable inventor whose contributions continue to influence the pharmaceutical landscape. With her impressive portfolio of patents and collaborations, she remains a key figure in the ongoing pursuit of innovative solutions in medicine. Her work not only showcases her inventiveness but also underscores the importance of collaboration in achieving significant breakthroughs in health and therapeutics.

Profile summary based on public USPTO records.